Companies: 10,795·Total market cap: $144.5T
Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILDNASDAQHealthcare● Active
$129.16
$-0.02(-0.02%)
Market Cap$160.4B
P/E Ratio—
52W High$157.29
52W Low$104.46
Overview

Gilead Sciences, Inc. (GILD) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

GILD · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$10.61B▼ -8.3% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$7.56B
cashAndCashEquivalents
Short-Term Investments
$3.04B
shortTermInvestments
YoY Change vs Prior Year
-8.3%
vs prior fiscal year
Latest Quarter
$9.82B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$10.61BCash on Hand
Total Debt$24.59BTotal Debt
Net Cash / Net Debt−$13.99BNet Debt Position
Cash vs Debt Ratio
Cash 30%Debt 70%

Gilead Sciences, Inc. carries a net debt position of $13.99B. Total debt ($24.59B) exceeds cash on hand ($10.61B). Gilead Sciences, Inc. cash vs debt ratio: 30% cash / 70% debt.

Net Cash = Cash & ST Investments − Total Debt$10.61B − $24.59B = −$13.99B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
GILD annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$10.61B-8.3%
Dec 31, 2024$11.57B+59.3%
Dec 31, 2023$7.26B+13.8%
Dec 31, 2022$6.38B-2.1%
Dec 31, 2021$6.52B-12.0%
GILD cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%
#3
Gilead Sciences, Inc.
Gilead Sciences, Inc.YOU
GILD
$10.61B6.6%
#4
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#5
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Gilead Sciences, Inc. (GILD) cash on hand as of December 31, 2025 is $10.61B, comprising $7.56B in cash and cash equivalents (CCE) plus $3.04B in short-term investments — reported as Gilead Sciences, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Gilead Sciences, Inc. cash reserves or cash position.

Gilead Sciences, Inc. annual cash on hand history shows decreased -8.3% in 2025: decreased -8.3% in 2025. Gilead Sciences, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Gilead Sciences, Inc. carries total debt of $24.59B against cash of $10.61B, resulting in a net debt position of -$13.99B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

GILD cash on hand · 5 questions

As of December 31, 2025, Gilead Sciences, Inc. (GILD) has $10.61B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $7.56B in cash and cash equivalents (CCE) plus $3.04B in short-term investments. Latest quarter (March 31, 2026): $9.82B. Data sourced from the annual 10-K filing via FMP.

GILD cash on handGILD cash reservesGILD cash 2025how much cash does GILD have

▸ Source: FMP /balance-sheet-statement · US GAAP · Gilead Sciences, Inc. · Gilead Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025